Multiple secondary data analyses of TORDIA have identified important predictors of treatment response and relapse .
To up date a comparative effectiveness review ( 1980–2011 ) of treatments for adolescents whose depressive episode or disorder ( MDE/MDD ) did not respond to one or more trials of SSRI antidepressants .
Anhedonia predicts poorer recovery among youth with selective serotonin reuptake inhibitor treatment-resistant depression.
OBJECTIVE To identify symptom dimensions of depression that predict recovery among  selective serotonin reuptake inhibitor ( SSRI ) treatment-resistant adolescents undergoing second-step treatment . METHOD The Treatment of Resistant Depression in Adolescents ( TORDIA ) trial included 334 SSRI treatment-resistant youth r and omized to a medication switch , or a medication switch plus CBT .  This study examined five established symptom dimensions ( Child Depression Rating Scale-Revised ) at baseline as they predicted recovery over 24 weeks of acute and continuation treatment . The two indices of recovery that were evaluated were time to remission and number of depression-free days . RESULTS Multivariate analyses examining all five depression symptom dimensions simultaneously indicated that anhedonia was the only dimension to predict a longer time to remission , and also the only dimension to predict fewer depression-free days . In addition , when anhedonia and CDRS-total score were evaluated simultaneously , anhedonia continued to uniquely predict longer time to remission and fewer depression-free days . CONCLUSIONS Anhedonia may represent an important negative prognostic indicator among treatment-resistant depressed adolescents . Further research is needed to eluci date neurobehavioral underpinnings of anhedonia , and to test treatments that target anhedonia in the context of overall treatment of depression
Multiple secondary data analyses of TORDIA have identified important predictors of treatment response and relapse .
To up date a comparative effectiveness review ( 1980–2011 ) of treatments for adolescents whose depressive episode or disorder ( MDE/MDD ) did not respond to one or more trials of SSRI antidepressants .